Natco Pharma seeks approval for Molnupiravir capsules for use in COVID-19 treatment

According to a press release from the city-based drug maker, pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3xk5Ml7
via IFTTT